Literature DB >> 9116389

The increase in spinal bone density that occurs in response to fluoride therapy for osteoporosis is not maintained after the therapy is discontinued.

J R Talbot1, M M Fischer, S M Farley, C Libanati, J Farley, A Tabuenca, D J Baylink.   

Abstract

In 44 osteoporotic subjects who had been treated with fluoride for 37 +/- 16 months, the fluoride was discontinued because they had shown fluoride-dependent increases in trabecular spinal bone densities from low initial levels (below the fracture threshold) to values that were equivalent to normal peak bone densities in the spines of young adults. During the subsequent period, after discontinuation of the fluoride therapy (i.e. 19 +/- 9 months), spinal bone density decreased in 73% of the subjects (i.e. 32 of 44, p < 0.03), at a rate that was comparable to the rate of the previous gain that had occurred during the treatment with fluoride (i.e. -3.23 +/- 2.39 mg/cm3 per month, compared with + 3.91 +/- 1.96 mg/cm3 per month in this, subgroup of patients, p < 0.001). Although 9 of the 44 subjects showed continuing increases in spinal bone density after discontinuation of the fluoride therapy, spinal bone density decreased in the entire group of 44 at an average rate of -1.02 +/- 4.72 mg/cm3 per month (p < 0.001, compared with the rate of the previous gain during the treatment with fluoride; i.e. +3.83 +/- 1.82 mg/cm3 per month). Surprisingly, our data showed that the rate of decrease in spinal bone density during the post-fluoride period was not affected by concurrent (undesigned) treatment with calcium, calcium plus estrogen, or calcium plus calcitriol. The cessation of fluoride therapy was also associated with a decrease in serum alkaline phosphatase activity (i.e. a decrease from the elevated levels that were observed during the period of fluoride therapy, back to the original, pre-treatment levels; p < 0.001), and that the rate of spinal bone loss after cessation of fluoride could be correlated with the prior rate of increase in serum alkaline phosphatase activity that had occurred during the treatment with fluoride (n = 44, r = 0.312, p = 0.039). Together, the observations from this retrospective analysis of data obtained from our clinical subjects suggest that fluoride-treated osteoporotic subjects who have exhibited increases in trabecular spinal bone density are at risk for bone loss after discontinuation of the fluoride therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9116389     DOI: 10.1007/bf01629576

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  21 in total

1.  Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures.

Authors:  C Y Pak; K Sakhaee; J E Zerwekh; C Parcel; R Peterson; K Johnson
Journal:  J Clin Endocrinol Metab       Date:  1989-01       Impact factor: 5.958

2.  Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

Authors:  B L Riggs; S F Hodgson; W M O'Fallon; E Y Chao; H W Wahner; J M Muhs; S L Cedel; L J Melton
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

3.  Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease.

Authors:  K Ueda; A Saito; H Nakano; M Aoshima; M Yokota; R Muraoka; T Iwaya
Journal:  J Pediatr       Date:  1980-11       Impact factor: 4.406

4.  Treatment of osteoporosis with fluoride, calcium, and vitamin D.

Authors:  D Briancon; P J Meunier
Journal:  Orthop Clin North Am       Date:  1981-07       Impact factor: 2.472

5.  Skeletal alkaline phosphatase activity as a bone formation index in vitro.

Authors:  J R Farley; D J Baylink
Journal:  Metabolism       Date:  1986-06       Impact factor: 8.694

6.  Treatment of primary osteoporosis with fluoride and calcium. Clinical tolerance and fracture occurrence.

Authors:  B L Riggs; S F Hodgson; D L Hoffman; P J Kelly; K A Johnson; D Taves
Journal:  JAMA       Date:  1980-02-01       Impact factor: 56.272

7.  Production of new trabecular bone in osteopenic ovariectomized rats by prostaglandin E2.

Authors:  S Mori; W S Jee; X J Li
Journal:  Calcif Tissue Int       Date:  1992-01       Impact factor: 4.333

8.  Partial loss of anabolic effect of prostaglandin E2 on bone after its withdrawal in rats.

Authors:  H Z Ke; X J Li; W S Jee
Journal:  Bone       Date:  1991       Impact factor: 4.398

9.  Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats.

Authors:  M Gunness-Hey; J M Hock
Journal:  Bone       Date:  1989       Impact factor: 4.398

10.  Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis.

Authors:  B L Riggs; W M O'Fallon; A Lane; S F Hodgson; H W Wahner; J Muhs; E Chao; L J Melton
Journal:  J Bone Miner Res       Date:  1994-02       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.